1. Integrase inhibitors to treat HIV/AIDS;Pommier;Nat Rev Drug Discov,2005
2. Raltegravir versus efavirenz regimens in treatment-naive HIV-1 infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses;Lennox;J Acquir Immune Defic Syndr,2010
3. Raltegravir with optimized background therapy for resistant HIV-1 infection;Steigbigel;N Engl J Med,2008
4. Eron J, Rockstroh J, Reynes J, et al. QDMRK, a phase III study of the safety and efficacy of once-daily vs twice daily RAL in combination therapy for treatment-naïve HIV-infected patients. 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; February 27–March 2, 2011. Abstr 150LB.
5. Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection;Klibanov;Curr Opin Investig Drugs,2009